VCs Warn New Device Tax Could Reduce Investments
This article was originally published in The Pink Sheet Daily
Executive Summary
Beyond the 2.3% device excise tax rate set to begin in 2013 under the recently enacted health care reform bill, VC's are concerned with potential changes in the regulatory and reimbursement environment as FDA considers revamping its 510(k) program and reliance increases on comparative effectiveness assessments.